BioPharma Dive July 16, 2024
The startup will use the financing to advance a pair of cardiovascular medicines and potentially add new therapies to its portfolio.
Dive Brief:
- Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build its portfolio of heart disease drugs.
- Cardurion will use the funds to advance a pair of medicines into mid- and late-stage testing, run studies in newer indications and potentially acquire other assets for cardiovascular diseases. The round comes two months after the startup detailed data from a Phase 2 trial in heart failure.
- Ascenta Capital led the financing, which involved NEA, GV, Bain Capital Life Sciences and a handful of other investors. Bain has already invested heavily...
Today's Sponsors
Today's Sponsor